TSX earnings scorecard: How fourth-quarter results have fared so far

Share

Globe editors have posted this research report with permission of Thomson Reuters I/B/E/S. This should not be construed as an endorsement of the report's recommendations. For more on The Globe's disclaimers please read here. The following is excerpted from the report:

EARNINGS HIGHLIGHTS

Q4 2017 Y/Y Blended Earnings Growth Estimates:

• TSX Composite (.GSPTSE) = 17.0 per cent
• Ex-Energy = 14.0 per cent
• Valeant Pharmaceuticals International Inc (VRX-TO) = -29.8 per cent
• Healthcare Ex-VRX = 5.3 per cent
• TSX Composite Ex-VRX = 17.7 per cent

Q4 2017 Performance vs. Earnings Expectations:

Seven per cent of the TSX Composite  companies have reported Q4 2017 EPS. Of the 12 companies in the index that have reported earnings to date for Q4 2017:

• 56.3 per cent reported above analyst expectations
• 31.3 per cent reported below analyst expectations

REVENUE HIGHLIGHTS

Q4 2017 Y/Y Blended Revenue Growth Estimates:

• TSX Composite  = 15.2 per cent
•  Ex-Energy = 14.4 per cent
• Valeant Pharma  = -16.8 per cent
• Healthcare Ex-Valeant Pharma  = 12.4 per cent
• TSX Composite Ex-Valeant Pharma = 15.6 per cent

Q4 2017 Performance vs. Revenue Expectations:

Of the TSX Composite companies that have reported revenue to date for Q4 2017:

• 50.0 per cent reported above analyst expectations
• 43.8 per cent reported below analyst expectations

Click here to see a full copy of the Thomson Reuters I/B/E/S TSX Composite Earnings Scorecard.

Globe app users click here for the full report

Read other research reports here.